ARWR
Arrowhead Pharmaceuticals, Inc.
ARWR lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to grow, though they disagree widely on how much.
ARWR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
ARWR's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
ARWR PE Valuation
ARWR has no meaningful PE right now: it lost money over the past year.
ARWR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARWR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
ARWR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.11 | -$5.10 |
| Q2 2026 | -$2.18 | -$0.92 |
| Q1 2026 | -$2.08 | -$0.70 |
| Q4 2025 | $1.60 | +$6.75 |
| Q3 2025 | -$0.01 | +$4.99 |
| Q2 2025 | -$1.26 | +$3.40 |
| Q1 2025 | -$1.38 | +$2.86 |
| Q4 2024 | -$5.15 | -$2.38 |
ARWR lost $5.11 per share over the past year, and its loss has widened in each of the last three quarters.
ARWR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.8M | -85% |
| Q2 2026 | $75.3M | +171% |
| Q1 2026 | $73.7M | -86% |
| Q4 2025 | $264M | +10461% |
| Q4 2024 | $2.5M | -30% |
| Q4 2023 | $3.6M | -94% |
| Q3 2023 | $16.1M | -49% |
| Q2 2023 | $15.8M | -51% |
ARWR's revenue has slid since its 2025 peak: $38M last quarter, down 85% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1155% | -1173 points |
| Q2 2026 | -226% | +370 points |
| Q1 2026 | -192% | -262 points |
| Q4 2025 | 15% | +6472 points |
| Q3 2025 | 17% | N/A |
| Q2 2025 | -596% | N/A |
| Q1 2025 | 70% | N/A |
| Q4 2024 | -6456% | -2611 points |
ARWR's operating margin was −1155% last quarter, down 1172 points from the same quarter a year ago, near the bottom of its range since 2019.
ARWR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$195.8M | -1606% |
| Q2 2026 | -$181.3M | -$24.2M |
| Q1 2026 | $81.9M | -82% |
| Q4 2025 | $11.3M | +$165.1M |
| Q3 2025 | $13M | +$174.5M |
| Q2 2025 | -$157.1M | -$27.2M |
| Q1 2025 | $454.8M | +$581.2M |
| Q4 2024 | -$153.8M | +$32.7M |
ARWR has burned cash in most quarters: −$284M over the past year, against $157M the year before.
ARWR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -1.7M shares |
| 1 year | +5.9% | +7.9M shares |
| 3 years | +33% | +34.9M shares |
| 5 years | +37% | +37.9M shares |
| Available history | +46% | +44.5M shares |
ARWR has 142M diluted shares, up 5.9% from a year ago.
ARWR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 0.0x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q1 2020 | -51.3x | Net Cash |
| Q4 2019 | -9.3x | Net Cash |
ARWR has more cash than debt.
ARWR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.8 | Oversold |
| Stochastic | 6.6 | Oversold |
ARWR's weekly RSI is 30 (oversold) and its Stochastic is 7 (oversold).
ARWR PE vs Healthcare Sector
| Metric | ARWR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARWR has no meaningful PE right now: it lost money over the past year.
ARWR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.0 | 20% below |
| 20 week MA | $73.0 | 35% below |
| 50 week MA | $70.0 | 33% below |
| 100 week MA | $46.1 | 2.3% above |
| 200 week MA | $37.1 | 27% above |
ARWR has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 27% above its 200-week average.
ARWR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $64.9 | $84.2 | +30% |
| 2021 | $84.2 | $70.3 | -17% |
| 2022 | $70.3 | $38.3 | -45% |
| 2023 | $38.3 | $30.6 | -20% |
| 2024 | $30.6 | $19.0 | -38% |
| 2025 | $19.0 | $70.2 | +270% |
| 2026 YTD | $70.2 | $47.2 | -33% |
ARWR's yearly returns have swung widely, from +270% in 2025 to −45% in 2022. It's down 33% so far in 2026.